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Background: Sesamol, a component of sesame seed oil, exhibited significant antioxidant activity in a battery of
in vitro and ex vivo tests including lipid peroxidation induced in rat liver homogenates. Latter established its
potential for hepatoprotection. However, limited oral bioavailability, fast elimination (as conjugates) and tendency
towards gastric irritation/toxicity (especially forestomach of rodents) may limit its usefulness. Presently, we packaged
sesamol into solid lipid nanoparticles (S-SLNs) to enhance its biopharmaceutical performance and compared the
efficacy with that of free sesamol and silymarin, a well established hepatoprotectant, against carbon tetrachloride
induced hepatic injury in rats, post induction. A self recovery group in which no treatment was given was used to
observe the self-healing capacity of liver.
Methods: S-SLNs prepared by microemulsification method were administered to rats post-treatment with CCl4
(1 ml/kg body weight (BW) twice weekly for 2 weeks, followed by 1.5 ml/kg BW twice weekly for the subsequent
2 weeks). Liver damage and recovery on treatment was assessed in terms of histopathology, serum injury markers
(alanine aminotransferase, aspartate aminotransferase), oxidative stress markers (lipid peroxidation, superoxide
dismutase, and reduced glutathione) and a pro-inflammatory response marker (tumor necrosis factor alpha).
Result: S-SLNs (120.30 nm) at a dose of 8 mg/kg BW showed significantly better hepatoprotection than
corresponding dose of free sesamol (FS; p < 0.001). Effects achieved with S-SLNs were comparable with silymarin
(SILY), administered at a dose of 25 mg/kg BW. Self recovery group confirmed absence of regenerative capacity of
hepatic tissue, post injury.
Conclusion: Use of lipidic nanocarrier system for sesamol improved its efficiency to control hepatic injury. Enhanced
effect is probably due to: a) improved oral bioavailability, b) controlled and prolonged effect of entrapped sesamol and
iii) reduction in irritation and toxicity, if any, upon oral administration. S-SLNs may be considered as a therapeutic option
for hepatic ailments as effectiveness post induction of liver injury, is demonstrated presently.
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Several of the drugs recommended for the treatment of
liver diseases tend to show adverse effects on the liver
function [1]. As the current available choice of useful
drug treatments for hepatic dysfunction is highly limited
[1], hence there is a continuous search for safe, efficient
and alternative therapeutic options [2]. Oxidative stress,* Correspondence: indupalkaur@yahoo.com
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to initiate and regulate the progression of liver disease,
independent of the etiologic agent [3]. Thus, phyto-
chemicals with significant antioxidant activity are being
explored extensively for the treatment of liver disease.
Carbon tetrachloride (CCl4) induced liver injury is the
best-characterized animal model of xenobiotic-induced
free radical-mediated hepatotoxicity [4]. CCl4 metabol-
ism begins with the formation of trichloromethyl free
radical, CCl3* through the action of the mixed function
cytochrome P450 oxygenase system of the endoplasmicicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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gen intermediates and causes lipid peroxidation (LPO).
Latter is responsible for hepatocellular damage and en-
hanced production of connective tissue [6,7]. CCl3*
binds to cellular molecules (nucleic acid, protein, lipid),
impairing crucial cellular processes such as lipid metab-
olism, and resulting in fatty degeneration i.e. steatosis
[8]. It can also react with oxygen to form the trichloro-
methyl peroxy radical CCl3OO*, a highly reactive species
which initiates the chain reaction of LPO as it attacks
and destroys polyunsaturated fatty acids, in particular
those associated with phospholipids [8].
Sesamol is a phenol component of sesame oil [9] and
is formed by hydrolysis of sesamolin during thermal oxi-
dation [10]. Sesamol, 5-hydroxy-1, 3-benzodioxole or
3,4-methylenedioxyphenol is a well-established antioxi-
dant molecule [11-13]. Its antioxidant activity is attrib-
uted to the presence of the benzodioxole group in its
ring, which scavenges hydroxyl radical to produce an-
other antioxidant molecule 1,2-dihydroxybenzene [14]
that assigns significant hepatoprotective effects to sesa-
mol. Oral bioavailability (BA) of 35.5 ± 8.5% has been re-
ported for sesamol in Sprague Dawley rats [15]. Further,
sesamol conjugated metabolites were found to be widely
distributed in rat tissues, with the highest concentrations
in the liver and kidneys upon oral administration of
100 mg/kg BW in rats, with their rapid elimination via
urine and feces within 0–4 h [16]. The Carcinogenic Po-
tency Database indicates that sesamol could be a poten-
tial cause of forestomach cancers in rodents with
determined TD50 values of 1.35 and 4.5 g/kg/day dose in
mice and rats respectively [17]. Although the point is
not of much concern considering that there are no for-
estomachs in humans and the TD50 dose is much higher
than the pharmacological per oral dose of 50–100 mg/
kg/day reported thus far, however, the observed effect
may however be attributed to its irritant nature due to
the phenolic group present in its structure [18].
Sesamol has been reported to possess hepatoprotective
properties [19-26] in several models of hepatotoxicity. It
may however be noted that sesamol till date has been
evaluated in acute model of hepatotoxicity carried for a
single dose administration, except for a study wherein
sesamol was repetitively administered subcutaneously at
a dose of 10 mg/kg, at 0, 6, 12, 18, 24, 30, 36, and 42 h
after cecal ligation and puncture, in rats [19]. Sesamol
was invariably administered parenterally through sub-
cutaneous route [19,20,23] or intra peritoneal (i.p) route
[21,22] in these studies. Further antioxidant effects in
terms of reduced glutathione (GSH), alanine amino-
transferase (ALT), aspartate aminotransferase (AST) and
LPO were observed mainly at doses ≥ 10 mg e.g. 10 mg
[19,22], 20 mg [20] and 41 mg [21] respectively. In an
early report the protective effects of sesamol and itsrelated compounds on CCl4 induced liver injury in rats
was studied [26]. Sesamol exhibited significant effect in
case of i.p, subcutaneous and oral administration by alle-
viating ALT, AST, lactate dehydrogenase, alkaline phos-
phatase, direct bilirubin and total bilirubin parameters.
However, the study was an acute study wherein CCl4 was
administered at a dose of 0.3 ml/kg and treatment with
sesamol was given 2 h prior or after. Even at a dose as high
as 276.24 mg given orally complete restoration of the ele-
vated parameters was not achieved. Previously we have re-
ported that sesamol could be used for preventive therapy
for CCl4 induced sub-chronic hepatotoxicity when loaded
into a suitable delivery system at a dose of 8 mg/kg [27].
In view of fast elimination, low BA, an irritant nature
and absence of extensive sub-chronic/chronic studies
evaluating hepatoprotective effects of sesamol, it was
presently proposed to explore the therapeutic and hepa-
toprotective potential of sesamol loaded into solid lipid
nanoparticles (SLNs). It is noteworthy that the present
study evaluated the ability of bioavailable sesamol (S-
SLNs) to provide hepatoprotection post induction of
liver injury. This is in sharp contrast to the proposed
protective role of these natural agents upon pretreat-
ment. SLNs are an excellent colloidal carrier system
[28,29] whose small size (<200 nm) helps to overwhelm
the reticuloendothelial system (RES) pick up such that
these particles recirculate or pass several times through
liver tissues thus achieving an enhanced (both intensity
and duration) effect of the entrapped agent [27,30].
A well established hepatoprotective agent silymarin
(SILY) [31] was used to compare the efficacy of S-SLNs and
free sesamol (FS). Additionally, a self recovery (SR) group
which did not undergo any treatment after induction of
hepatotoxicity was also included in the study to rule out
false implications of the therapy. The objectives of the
present study were to evaluate the efficacy of S-SLNs in
terms of serum biochemical markers of liver injury i.e. ALT,
AST, antioxidant markers, a pro-inflammatory marker i.e.
tumor necrosis factor-α (TNF-α) and histopathological in-
vestigations, in CCl4 induced liver injury in rats. However,
only the basic histological, biochemical and molecular stud-
ies (due to limitation of animals to be used and funds avail-
able) were selected as evaluation parameters because the
main objective of the study was not to elicit the mechanism
of action of sesamol which is already well illustrated, but to
establish the hepatoprotective superiority of the formulated
S-SLNs over the free sesamol form– (i) upon oral adminis-
tration, (ii) at clinically relevant doses, and (iii) as thera-
peutic agents for chronic liver diseases.
Methods
Materials
Sesamol was obtained as a free gift from Jubilant Life Sci-
ences (Noida, Uttar Pradesh, India); Compritol 888 ATO®
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Media, India); Tween 80 (S.D. Fine Chemicals, India) and
CCl4 (Merck) were also used in the study. All other che-
micals and reagents were of analytical grade.
Preparation of S-SLNs
SLNs were prepared by the microemulsification method,
as reported in our previous work [27]. Briefly, polysorbate
80 (45.45%), soy lecithin (0.58%) and water were placed to-
gether in a beaker and heated to the lipid melting
temperature. Lipid (7.27%) was also melted at 82–85°C
separately. Sesamol was added to the aqueous phase con-
taining polysorbate 80, following which the hot aqueous
emulsifier mix, was dropped at once into the lipid melt,
under magnetic stirring to obtain a clear microemulsion.
The hot microemulsion thus formed, was transferred into
an equivalent amount of cold water (~2°C) under continu-
ous mechanical stirring (5000 rpm) for 1.5 h. In the aque-
ous medium, SLNs are formed by crystallization of the hot
lipid droplets present in the microemulsions [32]. The
prepared aqueous SLN dispersion was stored in a refriger-
ator until further analysis.
Characterization of SLNs
The average particle size, polydispersity index (PDI) and
zeta potential of SLN dispersion was determined using
DelsaNano C, Beckman Coulter, Inc. The morphology of
SLNs was examined using an electronic transmission
microscope (Hitachi H-100, Japan). The total drug con-
tent (TDC) and the % entrapment of sesamol in SLNs
were determined as described in our previous work
[27,33]. Briefly, TDC was estimated spectrophotometric-
ally at λmax of 294 nm by disrupting 1 mL of the SLN
dispersion using an appropriate volume of chloroform:
methanol (1:1, v/v). The % entrapment was estimated by
dialysis bag method [27,33] where 1 ml of S-SLN disper-
sion was dialysed against 100 ml of water to remove the
free sesamol, maintained at 37°C and stirred at 150 rpm,
using dialysis bag (12KDa, Hi Media, India). After 15 min
SLN dispersion remaining in the dialysis bag, i.e. the di-
alysate was disrupted with a suitable quantity of chloro-
form: methanol (1:1, v/v) and the clear solution was
analysed spectrophotometrically to give a direct measure
of the entrapped sesamol/ml of the SLN dispersion.
Animal model and experimental protocol
Male Wistar rats weighing 150 to 200 gm were used in
the study. The experimental protocols were approved by
the Institutional Animals Ethical Committee of Panjab
University, Chandigarh (letter no 5381/VCD 6/12/10,
meeting held on 29.11.10). Rats were fed standard chow
diet and tap water ad libitum. The animals were housed
4 to 5 per cage.Animals were randomly divided into different groups,
each having 6 animals except for the naive control (NC)
group and per se (PS) groups which comprised of 3 ani-
mals each. In the positive control (CCl4) group, hepatic
injury was induced by oral administration of 1 ml/kg
BW CCl4 (mixed with an equal volume of olive oil) twice
a week for first two weeks followed by 1.5 ml/kg body
weight (BW) for the subsequent two weeks. In the ve-
hicle control (VC) group 1 ml/kg BW olive oil was ad-
ministered twice a week for first two weeks and 1.5 ml/kg
for the subsequent two weeks. In the S-SLN group three
days after administering the last dose of CCl4 as in the
positive control group, S-SLNs were administered at a
dose of 8 mg/kg BW daily for four weeks. Similarly, in
the FS group, three days post last dose of CCl4, FS dis-
solved in distilled water was administered orally at a
dose of 8 mg/kg BW daily for four weeks. In SILY
group three days post last dose of CCl4, SILY (dispersed
in 0.7% w/v carboxy methyl cellulose in water) was ad-
ministered at a dose of 25 mg/kg BW [34] daily for four
weeks. In the SR group after the final dose of CCl4 was
administered, rats were left for self recovery for four
weeks. In the NC group the animals were kept on nor-
mal diet throughout the eight week period of study. In
the S-SLNs PS group after four weeks of normal diet S-
SLNs were administered to rats at a dose equivalent of
8 mg of sesamol/kg BW daily for four weeks. Similarly,
in the FS PS, after four weeks of normal diet, FS dis-
solved in distilled water was administered orally at a
dose of 8 mg/kg BW daily for four weeks. In blank-
SLNs per se group (Bla-SLNs PS) blank SLNs were ad-
ministered orally daily for four weeks after rats were
kept at normal diet for four weeks. In the CCl4 group
animals were sacrificed three days post final dose of
CCl4 i.e. on 32
nd day and all the other animals were
sacrificed on the 60th day, i.e. a day after the final treat-
ment schedule (no treatment in the case of NC, VC
and SR groups).
Blood sampling was done via retro-orbital plexus, in
ether anesthetized rats. Serum was isolated by centrifu-
ging blood samples at 4°C for 20 min at 4000 rpm and
was stored at −20°C. Rats were sacrificed by cervical dis-
location and their livers were harvested after the end of
each study. A part of the liver was stored at 10% buff-
ered formalin for histopathological examinations and the
remaining part was homogenized with 10% (w/v) cold
phosphate –buffered saline (PBS 0.1Mol/l, pH 7.4).
The oxidative stress parameters were determined in
the liver post –mitochondrial supernatant (PMS) pre-
pared by centrifuging rat liver homogenates in the
chilled phosphate buffer, pH 7.4 at 10,500 g for 20 min
at 4°C. The following tests were performed to assess
the therapeutic potential of S-SLNs and other groups
under study.
Figure 1 TEM micrograph of S-SLNS.
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Representative liver tissue of different groups was proc-
essed, stained with haematoxylin & eosin (HE) and exam-
ined under the light microscope for steatosis, inflammation,
necrosis, fibrosis and cirrhosis. The histological changes
were observed on HE stained sections [27,35]. Changes in
the histological parameters for liver tissue, i.e. fatty changes,
inflammation and fibrosis were graded as follows: (−) show-
ing no occurrence and +, ++, +++ and ++++ as mild,
medium, high and severe occurrences respectively.
Estimation of serum liver injury markers
Serum of animals of the respective groups stored at –
20°C was used to measure ALT and AST levels according
to Reitman & Frankel’s method [36]. For ALT estimation
0.5 ml of the substrate comprising 0.2 M alanine, 2.0 mM
ketoglutarate and 100 mM phosphate buffer, pH 7.4, was
taken. However, the substrate for AST comprised of 0.2 M
aspartate, 2.0 mM ketoglutarate and 100 mM phosphate
buffer, pH 7.4. Both serum AST & ALT was expressed as
nmoles/nL and was compared with sodium pyruvate as
the standard.
Estimation of antioxidant parameters
The oxidative stress parameters were determined in liver
PMS.
Estimation of LPO
The quantitative measurement of LPO in liver was done
according to the method of Wills [37]. The malondialde-
hyde (MDA) content, a measure of LPO, was assayed as
liver thiobarbituric acid reactive substances. The results
were expressed as nanomoles of MDA per milligram of
protein, using the molar extinction coefficient of the
chromophore as 1.56 × 105 M − 1 cm − 1.
Measurement of superoxide dismutase (SOD)
SOD activity was assayed according to the method of
Kono et al. [38]. SOD activity was expressed in terms of
units of SOD per milligram of protein (SOD units/mg Pr).
Estimation of GSH levels
GSH was estimated by the method of Jollow et al. [39].
The results were expressed as nmoles of GSH per μg of
protein (nmoles of GSH/μg Pr).
Estimation of pro-inflammatory cytokine, TNF-α
TNF-α levels were measured in liver homogenates using
an ELISA kit (RayBiotech, Inc). The assay was performed
according to the manufacturer protocol.
Statistical Analysis
Data expressed as mean ± standard deviation (SD), were
analysed through one way analysis of variance (ANOVA),followed by the Tukey test for comparison of various
treatments using Sigma stat 3.5. Differences were consid-




The average particle size, PDI and zeta potential of S-
SLNs was found to be 120.30 nm, 0.111 and −51.31 mV
respectively. When observed under TEM, S-SLNs were
found to be spherical in shape (Figure 1). The TDC and %
entrapment of S-SLNs were estimated to be 3.31 ±
0.01 mg/ml and 73.92 ± 2.49% respectively (n = 3).
Histological analysis
The hepatoprotective effects of S-SLNs were evaluated by
histological analysis. Representative views of liver sections
are shown in Figure 2 (a-f). Figure 2a represents the VC liver
sections stained with HE showing normal histoarchitecture.
The PS and NC groups showed features similar to VC group
and hence are not shown. However, liver tissue in the rats
treated with CCl4 revealed extensive liver injuries, character-
ized by fatty cells, inflammatory bridges and vascular bridges
(Figure 2b). Howsoever, treatment with S-SLNs (Figure 2c)
improved the state of steatosis, ameliorated inflammation as
compared to CCl4 group. In comparison, FS treatment did
not restore the histoarchitecture as indicated by the pres-
ence of steatosis, and dense portal inflammation (Figure 2d).
SILY group, also showed a significant improvement, with
medium steatosis and portal inflammation being evident in
Figure 2 Haemotoxylin and eosin (HE) stained liver section of vehicle control animals showing polyhedral hepatocytes (H), central vein (CV) and portal
vein (PV) (2a); rats administered CCl4 showing altered histoarchitecture characterized by fatty changes i.e. steatosis [1], inflammatory bridges [2] and vascular
bridges [3] 2(b); S-SLNs treated rats showing mild steatosis [4] and medium portal inflammation [5] 2(c); FS treated rats showing medium steatosis [6], high
inflammation [7]; SILY treated rats showing medium steatosis [8] and inflammation [9] 2(e); and untreated SR group showing altered histoarchitecture with
high occurrence of steatosis [10] and inflammation [11] 2(f). Representative views of each group are presented at 200X magnification.
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comparable to the S-SLNs group. The SR group showed
(Figure 2f) altered histoarchitecture with high occurrence of
steatosis and inflammation indicating that the liver is unable
to restore its architecture in the absence of any treatment.
The obtained results are in terms of the extent of hepatic in-
jury and compiled in Table 1.
Serum liver injury markers
Administration of CCl4 led to 2570.07% increase in
the ALT levels as compared to the VC group.However, S-SLNs and FS treatment significantly de-
creased the elevated ALT levels by 52.59 ± 2.37% and
34.12 ± 3.69% respectively. Results obtained with S-
SLNs were significantly better (p < 0.001) than CCl4,
FS and SR groups. The effect was, however compar-
able to SILY (as shown in Table 2), though the latter
was administered at a 3 times higher dose of 25 mg/kg
BW. Similarly, AST levels were increased by 890.89%
in the CCl4 group with respect to the VC group and
the level significantly decreased in S-SLNs (p < 0.001)
treated group as compared to the CCl4, FS and SR
Table 1 Histological grading of CCl4 induced hepatic
injury in male Wistar rats
Group Fatty changes Inflammation Fibrosis
NC - - -
VC - - -
S-SLNs PS - - -
FS PS - - -
Bla SLNs PS - - -
CCl4 ++++ ++++ ++++
S-SLNs + ++ ++
FS ++ +++ +++
SILY ++ ++ ++
SR +++ +++ ++++
-, normal occurrence; +, mild occurrence; ++, medium occurrence; +++, high
occurrence; ++++, severe occurrence.
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by 75.68 ± 3.61%. The latter may be expressed as a
4.13 times improvement as compared to a 2.09 times
improvement observed in the FS group.
Antioxidant parameters
LPO
LPO expressed as MDA levels increased significantly (p <
0.001) in CCl4 group as compared to NC and VC group.
There was attenuation in LPO as indicated by a significant
decrease in levels of MDA in S-SLNs (p < 0.001) group
with respect to CCl4 group. S-SLNs treatment was signifi-
cantly more effective (2.38 fold) in reducing (p < 0.001)
MDA levels as compared to SR (1.64 fold) group and FS
(1.96 fold; p < 0.05) group. The attenuation was compar-
able to SILY group (2.04 fold). There was no significant
difference in the values of NC, VC and PS groups
(Figure 3).
SOD levels
SOD levels were found to be significantly (p < 0.001) low
in CCl4 group as compared to NC and VC group.Table 2 % inhibition in ALT and AST levels with respect to CC
to VC group and alleviation of the hepatic damage in terms o
respect to CCl4
ALT Levels
Groups Dose (mg/kg) % Inhibition versus CCl4 group




S-SLNsa 8 52.59 ± 2.37 (1073.93 ± 166.43) 2.12
FS 8 34.12 ± 3.69 (1677.97 ± 298.08) 1.51
SILYa 25 48.84 ± 3.15 (1173.98 ± 166.43) 1.95
SR - 19.09 ± 1.38 (1677.97 ± 298.08) 1.23
Data are expressed as mean ± S.D (n = 6) except for fold change. aAll the groups are
similarly. CCl4 increased the ALT and AST levels by 2570.07% and 890.89% respectiv
and 0.27 ± 0.05 respectively; AST are 6.50 ± 0.61 and 0.93 ± 0.20 respectively. The acTreatment with S-SLNs however, increased the SOD
levels (4.19 times) significantly (p < 0.05) as compared to
FS (2.91 times) and SILY (3.01 times) groups. The SR
group showed 2.56 times improvement in SOD levels
(Figure 4), however the effects achieved in the S-SLNs
were significantly better (p = 0.001) than SR group.
There was no significant difference in the values of NC,
VC and PS groups.
GSH levels
The level of total GSH was significantly reduced (p <
0.001) by CCl4 as compared to the VC and NC group.
Treatment with S-SLNs countered the inhibitory effect
of CCl4 by significantly (p < 0.001) increasing (6.49
times) the GSH levels as compared to FS (4.81 times),
SILY (4.94 times) and SR (4.44 times) groups. Further-
more, Bla-SLNs PS and S-SLNs PS groups very interest-
ingly showed a significant increase in the GSH levels in
comparison to NC and VC groups (Figure 5).
Inflammatory response
The levels of the proinflammatory cytokine TNF-α were
determined in the liver. As shown in Figure 6, compared
with the VC group, level of TNF-α was found to be sig-
nificantly elevated in the CCl4 (1379.76 ± 128.85%)
group. S-SLN treatment significantly reduced (2.47
times) the elevated levels of TNF-α (p < 0.001) as com-
pared to FS (1.91 times) and SR groups (1.62 times).
However, SILY group showed vast improvement (4.34
times) which was higher than all other treatment groups.
There was no significant difference in the values of NC,
VC and PS groups.
Discussion
The present investigation was an endeavor to explore
hepatoprotective effects of S-SLNs in comparison to free
drug and silymarin and establish S-SLNs as a therapeutic
option for hepatic damage post its induction. Scarce data
[40] including couple from our laboratory [27,30] on thel4 group, % increase in ALT and AST levels with respect




% Inhibition versus CCl4 group




75.68 ± 3.61 (139.52 ± 51.44) 4.13
51.84 ± 5.88 (356.79 ± 53.86) 2.09
75.97 ± 4.04 (129.95 ± 31.47) 4.18
5.22 ± 2.22 (837.98 ± 148.87) 1.05
significantly different from each other at p ≤ 0.001 except for those marked
ely with respect to VC. Actual values for CCl4 and VC for ALT are 7.21 ± 0.35
tual values are expressed in units of nmoles/nL.
Figure 3 MDA levels after treatment with S-SLNs, FS, SILY and various
other control groups post CCl4 induced hepatic injury. Data are
expressed as mean ± S.D (n = 6); except NC and PS groups (n = 3). All
groups are significantly different from each other at p < 0.001 or p <
0.050 except for those marked similarly.
Figure 5 GSH levels after treatment with S-SLNs, FS, SILY and
various other control groups post CCl4 induced hepatic injury. Data
are expressed as mean ± S.D (n = 6); except NC and PS groups
(n = 3). All groups are significantly different from each other at
p < 0.001 or p < 0.050 except for those marked similarly.
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over free drugs is available on the utility of SLNs for
liver disorders.
S-SLNs with total drug content of 3.31 ± 0.01 mg/ml
and % entrapment of 73.92 ± 2.49% (n = 3), with an aver-
age particle size and zeta potential of 120.30 nm (PDI-
0.111) and −51.31 mV, respectively, were prepared by
the microemulsification method. The method of prepar-
ation and the formula have been optimized in our la-
boratory [18,33]. It may also be highlighted here that the
method of preparation and the formula optimized in our
laboratory [28,33] uses dilution of hot microemulsion
with a significantly small (1:1) quantity of cold water
(usual recommended volume is 1:25 to 1:100) such that
it results in a concentrated dispersion. Latter ensures (i)
a higher drug content/volume of the dispersion such
that suitable doses can be administered in smaller vol-
umes and, (ii) overcomes the need to concentrate theFigure 4 SOD levels following treatment with S-SLNs, FS, SILY and
various other control groups post CCl4 induced hepatic injury. Data are
expressed as mean ± S.D (n = 6); except NC and PS groups (n = 3). All
groups are significantly different from each other at p < 0.001 or
p < 0.050 except for those marked similarly.dispersion by dialysis or lyophilisation. Both of which
are time consuming and costly techniques.
Size of nanoparticles monitors their uptake, into
pathological and inflamed tissues by macrophages, or
delivery across the fenestrae of the liver sinusoid [41,42].
It has been reported that nanoparticles with a diameter
of less than 200 nm reach liver parenchymal cells and
generate significant effects [43,44]. Presence of tween 80
as a surfactant in these SLNs gives them an added ad-
vantage of hydrophilicity similar to that imparted by
PEGylation [27,30,44]. Nanoparticles having zeta poten-
tial > ± 25 mV are stable dispersions with little or no
chance of aggregation. Furthermore, a PDI of <0.3 con-
firms uniform distribution of nanosized particles in the
SLN dispersion with low or no incidence of micrometer
particles. The latter may also indirectly be taken to con-
firm that all particles are of nano size and there are no
aggregates. The small size of the stable and uniform S-
SLN dispersion is expected to result in cumulative up-
take by the pathological liver over prolonged period dueFigure 6 TNF-α levels after treatment with S-SLNs, FS, SILY and various
other control groups post CCl4 induced hepatic injury. Data are
expressed as mean ± S.D (n = 6); except NC and PS groups (n = 3). All
groups are significantly different from each other at p < 0.001 except
for those marked similarly.
Singh et al. BMC Complementary and Alternative Medicine  (2015) 15:142 Page 8 of 10to repetitive filtration and passes through a probable fa-
cilitated transport across the fenestrae of the liver sinu-
soids. He et al. [40] have reported 2.79 times improved
oral BA of SILY upon incorporation into SLNs (170.7 nm)
which could result in a better drug targeting to the liver.
Previously we have reported that drug released versus
time data for S-SLNs wherein the total amount of the
drug released upto 24 h is 69.8% while a fast release of
28.4% in initial 1 h indicated the burst release of the
drug either from the small sized nanoparticles or the re-
lease of the unentrapped drug [27]. Further, a controlled
release pattern was depicted during 6–11 h, where no
significant increase in the % drug released was observed
[27]. In the oral pharmacokinetics conducted by us
(Figure 7), in a separate study in mice, at a dose of 4
mg/kg BW, administered S-SLNs indicated a 1.32 times
better (p < 0.05) BA (AUC0-∞) than FS (unpublished
work). It may however be noted that the study was per-
formed in mice and at a lower dose of 4 mg/kg BW (8
mg/kg BW dose of sesamol was administered to rats
presently) and since the latter are usually fast metaboli-
sers so the effect achieved with S-SLNs in rats and also
in humans, may actually be more pronounced. Further, a
higher tmax (8 h) value observed for S-SLNs, in compari-
son to 1 h for FS, indicates a sustained effect, probably
achieved due to slow release of the drug from the lipidic
nanoparticles (unpublished work).
Presently, CCl4 administration lead to hepatic steato-
sis, inflammation, and the formation of the vascular and
fibrotic bridges between nodules as revealed by the
histological studies and these observations were similar
to previous reported studies [27,35]. Present investiga-
tions revealed improvement in histoarchitecture of liver
on treatment with S-SLNs which was significantly better
than FS and SR groups and comparable to the SILY
group. In an earlier report sesamol exhibited renoprotec-
tive effects in streptozotocin (STZ) induced diabetes inFigure 7 Plasma concentration-time profiles of S-SLNs and FS when
administered orally at a dose of 4 mg/kg to mice.* S here stands for
free sesamol i.e. FS.rats [45] as it modulated the release of profibrotic cyto-
kines i.e. tissue growth factor-1 beta (TGF-β1). Similar
effect in the present study may have led to reduction in
the fibrotic bridges in S-SLNs treated group and better
effects observed in comparison with FS and SR groups.
Administration of CCl4 to rats lead to a significant ele-
vation (p < 0.001) in the levels of serum liver injury
markers, i.e. ALT and AST in comparison with the un-
treated VC and NC group. Increase in AST and ALT
levels is attributed to the damaged structural integrity of
the liver, as these enzymes are cytoplasmic in location
and hence are released into the plasma due to the liver
cell damage [46]. Treatment with S-SLNs significantly
reduced the serum ALT and AST levels, which were sig-
nificantly better than FS group and was comparable to
SILY (as shown in Table 2), though the latter was adminis-
tered at a 3 times higher dose of 25 mg/kg BW. Sesamol
has exhibited anti-MMP-9 (matrix metallopeptidase 9)
activity against monocrotaline-induced SOS in rats [14].
MMP-9 is important for the breakdown and necrosis of
hepatocytes [47] resulting in the leakage of ALT and AST
from liver. Hence, it may indirectly indicate that the anti-
MMP-9 effect of sesamol [23] may protect against hepatic
tissue necrosis, by attenuating the increased levels of ALT
and AST.
S-SLNs treatment may lead to membrane stabilization
of hepatocytes which is indicated presently by the reduc-
tion of LPO. CCl4 hepatotoxicity is attributed to LPO
and increased MDA levels [48] in liver tissue. Adminis-
tration of S-SLNs significantly reduced (p < 0.001) the
CCl4 induced increase in MDA levels and the effect was
better (p < 0.05) than FS group. This may be assigned to
the higher cellular permeability of sesamol achieved by
S- SLNs [49]. S-SLNs with a polysorbate 80 and a
phospholipid coat of surfactant and co-surfactant re-
spectively, are expected to intermingle with the mem-
brane lipids of liver cells resulting in physiologically
significant effects as shown in the present study.
A decreased SOD activity observed in the CCl4 treated
group was attributable to its easy inactivation by lipid
peroxides or ROS. SOD is a sensitive index for the hepa-
tocellular damage [50]. Since treatment with S-SLNs sig-
nificantly lowered the levels of MDA or ROS, hence, as
expected SOD was significantly (p < 0.05) upregulated in
S-SLNs group. It is important to note here that S-SLNs
treatment was not only significantly more effective than FS
but also in comparison to a well established hepatoprotec-
tive and antioxidant SILY, presently in clinical use too [51].
GSH is a predominant low-molecular-weight thiol and
the most important nonenzyme antioxidant in mamma-
lian cells [52]. It effectively protects cells against oxida-
tive stress caused damage by scavenging free radicals,
removing hydrogen peroxide (H2O2), and suppressing
LPO [53]. In our study, treatment with S-SLNs increased
Singh et al. BMC Complementary and Alternative Medicine  (2015) 15:142 Page 9 of 10the levels of GSH significantly (p < 0.001) as compared
to all other groups. Further, even the S-SLNs PS and Bla
SLNs PS groups showed an increase in the levels of GSH
as compared to NC and VC groups. These results indicate
that the SLNs have a unique ability to increase the levels
of GSH in vivo. These results are similar to those observed
and reported by us previously [18,27]. Our formulation
contains soy lecithin (a type of phospholipid component
of biological cell membranes) which consists of 21%
posphatidylcholine, and was administered daily for a time
period of four weeks, and could probably lead to an in-
crease in the intrinsic levels of GSH in hepatic tissue. In-
take of phosphatidylcholine for a long duration is reported
to result in an increase in glutathione levels [54]. Even
though the % of soya lecithin in our formulation is very
small (0.58%) but since it is now incorporated into a highly
bioavailable form, i.e. SLNs, the effect may be observed
even at low concentrations.
Hepatic injury is associated with elevated TNF-α level as
observed presently in the CCl4 group and also reported
elsewhere [55]. TNF-α levels are elevated both in the infil-
trating inflammatory cells and hepatocytes in chronic liver
injuries, including viral or alcoholic liver diseases, hepa-
titis, ischemia, and biliary obstruction [56]. Exposure to
hepatotoxic chemicals facilitates TNF-α to induce necrotic
cell death and hepatic apoptosis [57]. Sesamol attenuated
TNF-α levels in STZ induced diabetes in rats [45] and in
our study also elevated levels of TNF- α were significantly
attenuated (p < 0.001) by S-SLN treatment and the effect
was significantly (p < 0.001) better than FS group.
Conclusion
S-SLNs treatment was not only significantly more effective
than FS but, also showed effects comparable to a well-
established hepatoprotective and antioxidant agent SILY.
It may however be noted here that the recommended and
presently used dose of SILY (25 mg/kg) is >3 times that
used for S-SLNs (8 mg/kg). Hence it may be indirectly
concluded that S-SLNs are a significantly better thera-
peutic than SILY. Significant research is now focused on
establishing the multiple biological roles of antioxidant
phytochemicals. However, in most of these cases, the ef-
fects remain confined to the in vitro laboratory experi-
ments due to lack of translation of their antioxidant
activity to physiological systems. Major limitations to the
latter are poor solubility, stability (proneness to oxidative
and photodegradation), permeability, and bioavailability
coupled with a fast metabolism of these molecules.
Furthermore the in vitro or preclinical doses at which the
effects are obtained are not translatable to human use.
Hence their biopharmaceutical enhancement is a must if
they have to ‘see the light’ of being clinically relevant. Al-
though solubility and BA of sesamol are significant, how-
ever its fast metabolism and subsequent eliminationindicates need to package it into a sustained/ prolonged
release carrier system to improve its T1/2 and hence mean
residence time in the body to elicit considerable physio-
logical effect. It may be noted that earlier reported data
uses higher doses and parenteral administration of sesa-
mol. Presently an orally administered formulation of sesa-
mol is reported. Furthermore the Bla-SLNs PS groups
confirm the absence of any adverse effects and safety of
the developed formulation. The study established that
sesamol could be used as a therapeutic agent for the treat-
ment of liver diseases provided it is loaded into a suitable
delivery system.
Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase;
BA: Bioavailability; BW: Body weight; Bla-SLNs: Blank-solid lipid nanoparticles;
CCl4: Carbon tetrachloride; DTNB: 5-5′ dithiobis-2-2 nitrobenzoic acid;
FS: Free sesamol; GSH: Reduced glutathione; HE: Haemotoxylin and eosin;
LPO: Lipid peroxidation; MDA: Malondialdehyde; NC: Naïve control; PMS:
Post –mitochondrial supernatant; PS: Per se; PDI: Polydispersity index;
ROS: Reactive oxygen species; S-SLNs: Sesamol loaded solid lipid
nanoparticles; SR: Self recovery; SLNs: Solid lipid nanoparticles;
SOD: Superoxide dismutase; SILY: Silymarin; TDC: Total drug content;
VC: Vehicle control.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NS has made contribution in conducting all experiments, acquisition of data,
analysis and drafting of the manuscript. NK has made contribution in
conception and design of the experiment. VK has made contribution in
carrying out experiments related to preparation and characterization of the
solid lipid nanoparticles. IPK has contributed in conception and design of the
experiment and interpretation of data, drafting and revising the manuscript
for intellectual content. All authors read and approved the final manuscript.
Acknowledgements
The authors are thankful to Sophisticated Analytical Instrumentation Facility
(SAIF), Panjab University, Chandigarh for TEM analysis.
Author details
1Department of Biotechnology, Panjab University, Chandigarh 160014, India.
2Department of Pharmaceutics, University Institute of Pharmaceutical
Sciences, Panjab University, Chandigarh 160014, India.
Received: 17 July 2014 Accepted: 17 April 2015
References
1. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver
diseases or damage. Liver Int. 2009;29:1457–66.
2. Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. J Appl Toxicol.
2008;28:93–103.
3. Morisco F, Vitaglione P, Amoruso D, Russo B, Fogliano V, Caporaso N. 144–150:
foods and liver health. Mol Aspects Med. 2008;29:144–50.
4. Rechnagel RO, Glende EAJ. Carbon tetrachloride hepatotoxicity: an example
of lethal cleavage. CRC Crit Rev Toxicol. 1973;2:263–97.
5. Slater TF. Free-radical mechanisms in tissue injury. Biochem J. 1984;222:1–15.
6. Liu SL, Degli-Esposti S, Yao T, Diehl AMA, Zern MA. Vitamin E therapy of
acute CCl4-induced hepatic injury in mice is associated with inhibition of
nuclear factor kappa β binding. Hepatology. 1995;22:1474–81.
7. Hernandez-Munoz R, Diaz-Munoz M, Chagoya de Sanchez V. Possible role of
cell redox state on collagen metabolism in carbon tetrachloride-induced
cirrhosis as evidenced by adenosine administration to rats. Biochim Biophys
Acta. 1994;1200:93–9.
Singh et al. BMC Complementary and Alternative Medicine  (2015) 15:142 Page 10 of 108. Weber LW, Boll MA, Stampfl A. Hepatotoxicity and mechanism of action of
haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol.
2003;33:105–39.
9. Elleuch M, Besbes S, Roiseux O, Blecker C, Attia H. Quality. Characteristics of
sesame seeds and by- products. Food Chem. 2007;103:641–50.
10. Mohamed HMA, Awatif II. The Use of sesame Oil Unsaponifiable. Matter as a
natural antioxidant. Food Chem. 1998;62:269–76.
11. Hemalatha G, Pugalendi KV, Saravanan R. Modulatory effect of sesamol on
DOCA-salt-induced oxidative stress in uninephrectomized hypertensive rats.
Mol Cell Biochem. 2013;379:255–65.
12. Suja KP, Jayalekshmy A, Arumughan C. Free radical scavenging behavior of
antioxidant compounds of sesame (Sesamum indicum L.) in DPPH (*)
system. J Agric Food Chem. 2004;52:912–5.
13. Chennuru A, Saleem MTS. Antioxidant, Lipid Lowering, and Membrane
Stabilization Effect of Sesamol against Doxorubicin-Induced Cardiomyopathy in
Experimental Rats. BioMed Res Int. 2013;2013:934239. doi:10.1155/2013/934239.
14. Kumagai Y, Lin LY, Schmitz DA, Cho AK. Hydroxyl radical mediated
demethylenation of (methylenedioxy) phenyl compounds. Chem Res
Toxicol. 1991;4:330–4.
15. Jan KC, Ho CT, Hwang LS. Bioavailability and tissue distribution of sesamol
in rat. J AgricFood Chem. 2008;56:7032–7.
16. Jan KC, Ho CT, Hwang LS. Elimination and metabolism of sesamol, a bioactive
compound in sesame oil, in rats. Mol Nutr Food Res. 2009;53:S36–43.
17. CBBD: http://toxnet.nlm.nih.gov/cpdb/chempages/SESAMOL.html. 2007.
18. Kakkar V, Mishra M, Chuttani K, Chopra K, Kaur IP. Delivery of sesamol
loaded solid lipid nanoparticles to the brain for menopause related
emotional and cognitive central nervous system derangements.
Rejuvenation Res. 2011;14:597–604.
19. Hsu DZ, Chen KT, Li YH, Chuang YC, Liu MY. Sesamol delays mortality and
attenuates hepatic injury after cecal ligation and puncture in rats: role of
oxidative stress. Shock. 2006;25:528–32.
20. Hsu DZ, Chien SP, Chen KT, Liu MY. The effect of sesamol on systemic
oxidative stress and hepatic dysfunction in acutely iron-intoxicated mice.
Shock. 2007;28:596–601.
21. Chandrasekaran VRM, Chien SP, Hsu DZ, Liu MY. Anti-hepatotoxic effects of
3,4-methylenedioxyphenol and N-acetylcysteine in acutely acetaminophen-
overdosed mice. Hum Exp Toxicol. 2011;30:1609–15.
22. Chandrasekaran VR, Hsu DZ, Liu MY. The protective effect of sesamol
against mitochondrial oxidative stress and hepatic injury in acetaminophen-
overdosed rats. Shock. 2009;32:89–93.
23. Periasamy S, Hsu DZ, Chen SY, Yang SS, Chandrasekaran VR, Liu MY.
Therapeutic sesamol attenuates monocrotaline-induced sinusoidal obstruction
syndrome in rats by inhibiting matrix metalloproteinase-9. Cell Biochem
Biophys. 2011;61:327–36.
24. Jnaneshwari S, Hemshekhar M, Thushara RM, Sundaram MS, Santhosh MS,
Sunitha K, et al. Sesamol Ameliorates Cyclophosphamide-Induced Hepatotoxicity
by Modulating Oxidative Stress and Inflammatory Mediators. Anticancer Agents
Med Chem. 2014;14:975–83.
25. Ohta S, Suzuki M, Sato N, Kamogawa A, Shinoda M. Protective effects of
sesamol and its related compounds on carbon tetrachloride induced liver
injury in rats. Yakugaku Zasshi. 1994;114:901–10.
26. Uchida M, Nakajin S, Toyoshima S, Shinoda M. Antioxidative effect of
sesamol and related compounds on lipid peroxidation. Biol Pharm Bull.
1996;19:623–6.
27. Singh N, Khullar N, Kakkar V, Kaur I P: Hepatoprotective effects of sesamol
loaded solid lipid nanoparticles in carbon tetrachloride induced
sub-chronic hepatotoxicity in rats. Environ Toxicol. 2014; doi:10.1002/tox.22064.
28. Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance
the oral bioavailability of curcumin. Mol Nutr Food Res. 2011;55:495–503.
29. Bhandari R, Kaur IP. Pharmacokinetics, tissue distribution and relative
bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm.
2013;441:202–12.
30. Singh N, Khullar N, Kakkar V, Kaur IP. Attenuation of Carbon Tetrachloride-
Induced Hepatic Injurywith Curcumin-Loaded Solid Lipid Nanoparticles.
BioDrugs. 2014;28:297–312.
31. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from
experimental pharmacology to clinical medicine. Indian J Med Res.
2006;124:491–504.
32. Manjunath K, Reddy S, Venkateswarlu V. Solid lipid nanoparticles as drug
delivery systems. Method Exp Clin. 2005;27:127–44.33. Kakkar V, Kaur IP. Preparation, characterization and scale-up of sesamol
loaded solid lipid nanoparticles. Nanotechnol Dev. 2012;2, e8.
34. Gopal N, Sengottuvelu S. Hepatoprotective activity of Clerodendrum inerme
against CCl4 induced hepatic injury in rats. Fitoterapia. 2008;79:24–6.
35. Dong MX, Jia Y, Zhang YB, Li CC, Geng YT, Zhou L, et al. Emodin protects
rat liver from CCl4-induced fibrogenesis via inhibition of hepatic stellate
cells activation. World J Gastroenterol. 2009;15:4753–62.
36. Reitman S, Frankel SA. A colorimetric method for the determination of
serum glutamic oxalacetic and glutamic pyruvic transaminases. Amer J Clin
Pathol. 1957;28:56–63.
37. Wills ED. Mechanisms of lipid peroxide formation in animal tissue. Biochem
J. 1966;99:667–76.
38. Kono Y. Generation of superoxide radical during autooxidation of
hydroxylamine and an assay for superoxide dismutase. Arch Biochem
Biophys. 1978;186:189–95.
39. Jollow D, Mitchell L, Zampaglione N, Gillete J. Bromobenzene induced liver
necrosis: protective role of glutathione and evidence for 3,4-bromobenzenoxide
as the hepatotoxic intermediate. Pharmacology. 1974;11:151–69.
40. He J, Hou S, Lu W, Zhu L, Feng J. Preparation, Pharmacokinetics and Body
Distribution of Silymarin-Loaded Solid Lipid Nanoparticles After Oral
Administration. J Biomed Nanotechnol. 2007;3:195–202.
41. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle
size on the cellular uptake efficiency of nanoparticles with the HepG2 cells.
J Control Release. 2007;118:7–17.
42. Liang HF, Yang TF, Huang CT, Chen MC, Sung HW. Preparation of
nanoparticles composed of poly(gamma-glutamic acid)-poly (lactide) block
copolymers and evaluation of their uptake by HepG2 cells. J Control
Release. 2005;105:213–25.
43. Hashida M, Takemura S, Nishikawa M, Takakura Y. Targeted delivery of
plasmid DNA complexed with galactosylated poly(L-lysine). J Control
Release. 1998;53:301–10.
44. Li L, Wang H, Ong ZY, Xu K, Ee PLR, Zheng S, et al. Polymer- and lipid-based
nanoparticle therapeutics for the treatment of liver diseases. Nano Today.
2010;5:296–312.
45. Kuhad A, Sachdeva AK, Chopra K. Attenuation of renoinflammatory cascade
in experimental model of diabetic nephropathy by sesamol. J Agric Food
Chem. 2009;57:6123–8.
46. Sallie R, Tredger JM, Williams R. Drugs and the liver part 1: testing liver
function. Biopharm Drug Dispos. 1991;12:251–9.
47. Ohashi N, Hori T, Chen F, Jermanus S, Eckman CB, Nakao A, et al. Matrix
metalloproteinase-9 contributes to parenchymal hemorrhage and necrosis
in the remnant liver after extended hepatectomy in mice. World J
Gastroenterol. 2012;18:2320–33.
48. Curtis JJ, Mortiz M. Serum enzymes derived from liver cell fraction and response
to carbon tetrachloride intoxication in rats. Gastroenterol. 1972;62:84–92.
49. Geetha T, Bhandari R, Kaur IP. Sesamol: An efficient antioxidant with
potential therapeutic benefits. Med Chem. 2009;5:367–71.
50. Feher J, Lengyel G. Silymarin in the Prevention and Treatment of Liver
Diseases and Primary Liver Cancer. Curr Pharm Biotechnol. 2012;13:210–7.
51. Javed S, Kohli K, Ali M. Reassessing bioavailability of silymarin. Altern Med
Rev. 2011;16:239–49.
52. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and
its implications for health. J Nutr. 2004;134:489–92.
53. Blair IA. Endogenous glutathione adducts. Curr Drug Metab. 2006;7:853–72.
54. Shukitt-Hale B, Erat SA, Joseph JA. Spatial learning and memory deficits
induced by dopamine administration with decreased glutathione. Free
Radic Biol Med. 1998;24:1149–58.
55. Roy S, Sannigrahi S, Majumdar S, Ghosh B, Sarkar B. Resveratrol regulates
antioxidant status, inhibits cytokine expression and restricts apoptosis in
carbon tetrachloride induced Rat hepatic injury. Oxid Med Cell Longev.
2011;703676:12.
56. Hernandez-Munoz I, Torre PDL, Sanchez-Alcazar JA, Garcia I, Santiago E,
Munoz-Yague MT, et al. Tumor necrosis factor αinhibits collagen α1(I) gene
expression in rat hepatic stellate cells through a G protein. Gastroenterol.
1997;113:625–40.
57. Berghe TV, Denecker G, Brouckaert G, Vadimovisch D, D’Herde KK,
Vandenabeele P. More than one way to die: methods to determine
TNF-induced apoptosis and necrosis. Methods Mol Med. 2004;98:101–26.
